Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Serzan, Michael T, Kumar, Princy N, Atkins, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246106/
https://www.ncbi.nlm.nih.gov/pubmed/32434789
http://dx.doi.org/10.1136/jitc-2020-000898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246106/
https://www.ncbi.nlm.nih.gov/pubmed/32434789
http://dx.doi.org/10.1136/jitc-2020-000898

Ejemplares similares